Rob Williamson discusses his successful career in biotech startups, focusing on Triumvira's innovative T-cell therapeutics in oncology. He shares insights on cancer therapeutics, dealmaking, and the future of the biotech industry.

Rob Williamson, President and COO of Triumvira Immunologics, brings over two decades of experience in biotechnology. He discusses the unpredictable nature of capital markets and shares his cautious optimism for future trends. The conversation highlights challenges in cell therapy, particularly with CAR-T treatments, and the industry's shift toward preventative solutions. Williamson also delves into the dynamics of biotech boards, emphasizing the need for supportive relationships. He reflects on resilience in the face of industry challenges, providing valuable insights into evolving healthcare strategies.